Targeting USP2 regulation of VPRBP-mediated degradation of p53 and PD-L1 for cancer therapy
The clinical success of restoring P53 for cancer therapy has been limited due to toxicity. Here, the authors identify USP2 as an upstream regulator of VPRBP-mediated degradation of p53 and PD-L1 and demonstrate the efficacy of combining USP2 inhibitor and PD-L1/PD-1 immune checkpoint blockade in can...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2023-04-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-023-37617-3 |